At IGEA Medical UK we have adopted the same professional scientific approach as our parent Company based in Italy, IGEA S.p.A.
IGEA has operated within the orthopaedic medical devices market for over 30 years, showing during this time an absolute focus on the understanding of patient’s conditions and developing therapies to improve their lives.
For over 12 years, through a commitment to research and innovation IGEA has partnered with leading scientific institutions across Europe and developed an innovative approach to treating cutaneous and sub-cutaneous tumours (cancers affecting the skin and below the skin’s surface) via the technique of clinical electroporation and electrochemotherapy using the IGEA CLINIPORATOR™ device.
In January 2011 an affiliate Company was launched in the UK with the aim of replicating the pan European success of the Oncology division of IGEA.
The technique of electrochemotherapy was developed in the early 1990s by Dr. L. M. Mir, of the French National Scientific Research Centre at the Gustave Roussy Institute in Paris.
It is currently used in over 110 clinical centres and Hospitals across Europe both in accepted clinical practice and for further research into the technique.
Its use is particularly indicated in patients with; melanoma and non-melanoma skin cancers (including basal cell carcinoma, squamous cell carcinoma, kaposi’s sarcoma); local recurrences or skin metastases from breast cancer, and head and neck cancers including oral cancer.
IGEA products and the CLINIPORATOR™ are not available in the USA.